Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report
Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report
复制标题
三例肝移植后丙型肝炎复发患者接受达拉他韦和阿舒瑞韦治疗：病例报告
作者：
T. Kawaoka;M. Imamura;Kei Morio;Yuki Nakamura;M. Tsuge;C. Nelson Hayes;Y. Kawakami;H. Aikata;H. Ochi;K. Ishiyama;K. Ide;H. Tashiro;H. Ohdan;K. Chayama
我们先前报道了特拉匹韦或西米匹韦联合聚乙二醇干扰素（PEG IFN）和利巴韦林（RBV）治疗肝移植（LT）后复发性丙型肝炎病毒（HCV）基因型1感染的数据。在这里，我们报告了三名患者，他们在达卡他韦和阿舒那匹韦治疗后获得了病毒应答，而对免疫抑制剂的血药浓度没有影响。第一例患者为57岁男性，患有HCV相关肝硬化，在活体供者LT后对PEG IFN/RBV无效。他接受了1 mg/天他克莫司治疗。第二例是一名63岁的男性，患有HCV相关肝硬化和肝细胞癌，在活体供者LT后对PEG IFN/RBV无效。他接受了1 mg/天他克莫司治疗。第三例是一名61岁的男性，患有HCV相关肝硬化。他接受了霉酚酸酯（MMF）治疗。在所有患者中，达卡他韦和阿舒那匹韦治疗4周后，TaqMan聚合酶链反应检测不到血清HCV RNA，在24周的治疗期间，未观察到他克莫司或MMF的血药浓度出现显著波动。没有观察到不良事件，所有患者在24周内接受了全剂量的达卡他韦和asunaprevir。所有患者治疗12周后血清HCVRNA均为阴性。达卡他韦和asunaprevir治疗显示出显著的病毒应答，对LT后复发的HCV基因型1感染的免疫抑制剂血液水平几乎没有影响。
We previously reported our data on telaprevir or simeprevir used in combination with pegylated interferon (PEG IFN) and ribavirin (RBV) for the treatment of recurrent hepatitis C virus (HCV) genotype 1 infection after liver transplantation (LT). Here, we report three patients who achieved viral responses with no effect on the blood concentrations of immunosuppressive agents following daclatasvir and asunaprevir treatment. The first patient was a 57‐year‐old man with HCV‐related liver cirrhosis who failed to respond to PEG IFN/RBV after living donor LT. He had been treated with 1 mg/day of tacrolimus. The second was a 63‐year‐old man with HCV‐related liver cirrhosis and hepatocellular carcinoma who failed to respond to PEG IFN/RBV after living donor LT. He had been treated with 1 mg/day of tacrolimus. The third was a 61‐year‐old man with HCV‐related liver cirrhosis. He had been treated with mycophenolate mofetil (MMF). Serum HCV RNA became undetectable by TaqMan polymerase chain reaction test after 4 weeks of daclatasvir and asunaprevir treatment in all patients, and no remarkable fluctuations in blood concentration were observed either in tacrolimus or in MMF during 24 weeks of therapy. No adverse events were observed, and all patients received the full dose of daclatasvir and asunaprevir over 24 weeks. Serum HCV RNA remained negative at 12 weeks after the end of treatment in all patients. The daclatasvir and asunaprevir treatment showed a remarkable viral response with little effect on blood levels of immunosuppressive agents for recurrent HCV genotype 1 infection after LT.
DOI：
--
发表时间：
2011
期刊：
Journal of Clinical Hepatology
影响因子：
--
作者：
Niu Jun-q
通讯作者：
Niu Jun-q
影响因子：
158.5
作者：
Sulkowski, Mark S.;Gardiner, David F.;Grasela, Dennis M.
通讯作者：
Grasela, Dennis M.
影响因子：
29.4
作者：
Forman, LM;Lewis, JD;Lucey, MR
通讯作者：
Lucey, MR